POP02 targets Diffuse Midline Glioma — the deadliest pediatric brain cancer, with no approved treatment and a 12-month median survival. First-in-class. Triple-action. IND-stage.
CNS tumors are the leading cause of cancer death in children. DMG — including DIPG — has defied every treatment attempted in 50 years of research.
Every conventional approach has failed. No chemotherapy, no targeted therapy, no immunotherapy has changed survival. This is the white space POP02 is designed to fill.
See the Full SciencePOP02 combines three independent anti-tumor mechanisms in one engineered adenoviral vector — the only triple-action platform designed for pediatric CNS malignancies.
POP02 replicates exclusively inside tumor cells, destroying cancer tissue directly while leaving healthy neural cells completely unharmed.
No systemic toxicity. POP02 activates T cells precisely inside the tumor — not throughout the body.
Blocks immune suppression at the TIM3 checkpoint, allowing the body's own defenses to sustain the anti-tumor response and prevent T-cell exhaustion.
POP02 is advancing toward IND submission, backed by robust preclinical efficacy and a safety profile inherited from the validated DNX2401 backbone.
| Asset | Indication | Preclinical | IND | Phase I | Phase II |
|---|---|---|---|---|---|
|
POP02
Oncolytic adenovirus · Triple action
Lead |
DMG / DIPG Pediatric |
|
|
|
|
| POP02 Platform expansion · GBM | Glioblastoma Adult |
|
|
|
|
Our founders hold senior author credits in Cancer Cell, NEJM, and Nature Communications. One has administered an oncolytic virus to a pediatric DMG patient — with observed clinical activity.
Popcorn Therapeutics is raising a pre-Series A round to fund IND submission and Phase I initiation in DMG/DIPG. Strong IP. Validated backbone. Zero competition in pediatric CNS triple-action. Contact us to receive the full investment package.